Roche persuades U.S. judge to toss $2M Accutane verdict

Roche ($RHHBY) has emerged victorious in its quest to reverse a $2.1 million verdict by a New Jersey jury in favor of a woman who blamed the Swiss pharma's acne med Accutane for her inflammatory bowel disease, Bloomberg reports. Plaintiff Gillian Gaghan said Roche failed to warn her of Accutane's risks. But according to the new opinion, "a prescription drug manufacturer fulfills its duty to warn if it provides adequate warnings to the prescribing physician, and it has no duty to ensure that the warning reaches the patient." Story